Is LONA or ZNTL more profitable?

Zentalis Pharmaceuticals' return on equity of -70.18% beat Athira Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Athira Pharma N/A -411.58% -225.73% Zentalis Pharmaceuticals N/A -70.18% -51.46%

Which has higher valuation and earnings, LONA or NERV?

Athira Pharma is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Athira Pharma N/A N/A -$105.61M -$4.21 N/A Minerva Neurosciences N/A N/A -$293.42M -$28.87 N/A

Is LONA or NERV more profitable?

Minerva Neurosciences' return on equity of 0.00% beat Athira Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Athira Pharma N/A -411.58% -225.73% Minerva Neurosciences N/A N/A -31.72%

Which has stronger earnings and valuation, LONA or CRDL?

Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Athira Pharma N/A N/A -$105.61M -$4.21 N/A Cardiol Therapeutics N/A N/A -$24.20M -$0.25 N/A

Is LONA or CRDL more profitable?

Cardiol Therapeutics' return on equity of -180.44% beat Athira Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Athira Pharma N/A -411.58% -225.73% Cardiol Therapeutics N/A -180.44% -140.28%

Athira Pharma (LONA) Competitors

$6.10 -0.33 (-5.05%)

As of 12:45 PM Eastern

Compare

LONA vs. ACOG, ZNTL, DERM, NERV, and CRDL

Should you buy Athira Pharma stock or one of its competitors? Athira Pharma's main competitors and comparable companies include Alpha Cognition (ACOG), Zentalis Pharmaceuticals (ZNTL), Journey Medical (DERM), Minerva Neurosciences (NERV), and Cardiol Therapeutics (CRDL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Athira Pharma compare to Alpha Cognition?

Athira Pharma (NASDAQ:LONA) and Alpha Cognition (NASDAQ:ACOG) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

Athira Pharma presently has a consensus price target of $17.33, indicating a potential upside of 169.57%. Alpha Cognition has a consensus price target of $18.00, indicating a potential upside of 104.55%. Given Athira Pharma's higher probable upside, research analysts clearly believe Athira Pharma is more favorable than Alpha Cognition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Alpha Cognition has higher revenue and earnings than Athira Pharma. Alpha Cognition is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$105.61M	-$4.21	N/A
Alpha Cognition	$10.22M	18.75	-$20.67M	-$1.10	N/A

Athira Pharma has a net margin of 0.00% compared to Alpha Cognition's net margin of -153.61%. Alpha Cognition's return on equity of -54.60% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-411.58%	-225.73%
Alpha Cognition	-153.61%	-54.60%	-43.47%

57.1% of Athira Pharma shares are owned by institutional investors. 25.7% of Athira Pharma shares are owned by insiders. Comparatively, 8.6% of Alpha Cognition shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Athira Pharma has a beta of 2.11, suggesting that its stock price is 111% more volatile than the broader market. Comparatively, Alpha Cognition has a beta of 2.32, suggesting that its stock price is 132% more volatile than the broader market.

In the previous week, Alpha Cognition had 3 more articles in the media than Athira Pharma. MarketBeat recorded 4 mentions for Alpha Cognition and 1 mentions for Athira Pharma. Athira Pharma's average media sentiment score of 1.82 beat Alpha Cognition's score of 0.54 indicating that Athira Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Athira Pharma	Very Positive
Alpha Cognition	Positive

Summary

Alpha Cognition beats Athira Pharma on 9 of the 14 factors compared between the two stocks.

How does Athira Pharma compare to Zentalis Pharmaceuticals?

Athira Pharma (NASDAQ:LONA) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.

Athira Pharma has a beta of 2.11, meaning that its stock price is 111% more volatile than the broader market. Comparatively, Zentalis Pharmaceuticals has a beta of 1.93, meaning that its stock price is 93% more volatile than the broader market.

57.1% of Athira Pharma shares are owned by institutional investors. 25.7% of Athira Pharma shares are owned by company insiders. Comparatively, 3.8% of Zentalis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Zentalis Pharmaceuticals' return on equity of -70.18% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-411.58%	-225.73%
Zentalis Pharmaceuticals	N/A	-70.18%	-51.46%

Athira Pharma has higher earnings, but lower revenue than Zentalis Pharmaceuticals. Athira Pharma is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$105.61M	-$4.21	N/A
Zentalis Pharmaceuticals	$67.43M	2.55	-$137.06M	-$1.95	N/A

Athira Pharma currently has a consensus target price of $17.33, indicating a potential upside of 169.57%. Zentalis Pharmaceuticals has a consensus target price of $7.50, indicating a potential upside of 212.50%. Given Zentalis Pharmaceuticals' higher probable upside, analysts plainly believe Zentalis Pharmaceuticals is more favorable than Athira Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Zentalis Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Zentalis Pharmaceuticals had 1 more articles in the media than Athira Pharma. MarketBeat recorded 2 mentions for Zentalis Pharmaceuticals and 1 mentions for Athira Pharma. Athira Pharma's average media sentiment score of 1.82 beat Zentalis Pharmaceuticals' score of 1.02 indicating that Athira Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Athira Pharma	Very Positive
Zentalis Pharmaceuticals	Positive

Summary

Zentalis Pharmaceuticals beats Athira Pharma on 8 of the 13 factors compared between the two stocks.

How does Athira Pharma compare to Journey Medical?

Athira Pharma (NASDAQ:LONA) and Journey Medical (NASDAQ:DERM) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends, institutional ownership and media sentiment.

Athira Pharma has a beta of 2.11, meaning that its stock price is 111% more volatile than the broader market. Comparatively, Journey Medical has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market.

57.1% of Athira Pharma shares are owned by institutional investors. Comparatively, 7.3% of Journey Medical shares are owned by institutional investors. 25.7% of Athira Pharma shares are owned by insiders. Comparatively, 14.5% of Journey Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Athira Pharma has a net margin of 0.00% compared to Journey Medical's net margin of -8.95%. Journey Medical's return on equity of -20.23% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-411.58%	-225.73%
Journey Medical	-8.95%	-20.23%	-6.60%

Journey Medical has higher revenue and earnings than Athira Pharma. Journey Medical is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$105.61M	-$4.21	N/A
Journey Medical	$61.86M	2.59	-$11.43M	-$0.22	N/A

In the previous week, Journey Medical had 2 more articles in the media than Athira Pharma. MarketBeat recorded 3 mentions for Journey Medical and 1 mentions for Athira Pharma. Athira Pharma's average media sentiment score of 1.82 beat Journey Medical's score of 0.87 indicating that Athira Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Athira Pharma	Very Positive
Journey Medical	Positive

Athira Pharma presently has a consensus price target of $17.33, indicating a potential upside of 169.57%. Journey Medical has a consensus price target of $14.00, indicating a potential upside of 146.48%. Given Athira Pharma's stronger consensus rating and higher possible upside, equities analysts plainly believe Athira Pharma is more favorable than Journey Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Journey Medical	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Athira Pharma beats Journey Medical on 8 of the 14 factors compared between the two stocks.

How does Athira Pharma compare to Minerva Neurosciences?

Athira Pharma (NASDAQ:LONA) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, dividends and analyst recommendations.

57.1% of Athira Pharma shares are held by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are held by institutional investors. 25.7% of Athira Pharma shares are held by insiders. Comparatively, 1.7% of Minerva Neurosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Minerva Neurosciences' return on equity of 0.00% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-411.58%	-225.73%
Minerva Neurosciences	N/A	N/A	-31.72%

Athira Pharma currently has a consensus target price of $17.33, suggesting a potential upside of 169.57%. Minerva Neurosciences has a consensus target price of $10.33, suggesting a potential upside of 310.05%. Given Minerva Neurosciences' higher probable upside, analysts clearly believe Minerva Neurosciences is more favorable than Athira Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Minerva Neurosciences	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Athira Pharma has a beta of 2.11, indicating that its share price is 111% more volatile than the broader market. Comparatively, Minerva Neurosciences has a beta of -0.1, indicating that its share price is 110% less volatile than the broader market.

Athira Pharma is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$105.61M	-$4.21	N/A
Minerva Neurosciences	N/A	N/A	-$293.42M	-$28.87	N/A

In the previous week, Minerva Neurosciences had 1 more articles in the media than Athira Pharma. MarketBeat recorded 2 mentions for Minerva Neurosciences and 1 mentions for Athira Pharma. Athira Pharma's average media sentiment score of 1.82 beat Minerva Neurosciences' score of 0.89 indicating that Athira Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Athira Pharma	Very Positive
Minerva Neurosciences	Positive

Summary

Athira Pharma beats Minerva Neurosciences on 8 of the 12 factors compared between the two stocks.

How does Athira Pharma compare to Cardiol Therapeutics?

Athira Pharma (NASDAQ:LONA) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, media sentiment, institutional ownership, valuation, profitability and risk.

Athira Pharma presently has a consensus price target of $17.33, suggesting a potential upside of 169.57%. Cardiol Therapeutics has a consensus price target of $10.00, suggesting a potential upside of 733.33%. Given Cardiol Therapeutics' higher possible upside, analysts clearly believe Cardiol Therapeutics is more favorable than Athira Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$105.61M	-$4.21	N/A
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.25	N/A

Athira Pharma has a beta of 2.11, meaning that its share price is 111% more volatile than the broader market. Comparatively, Cardiol Therapeutics has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market.

Cardiol Therapeutics' return on equity of -180.44% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-411.58%	-225.73%
Cardiol Therapeutics	N/A	-180.44%	-140.28%

57.1% of Athira Pharma shares are held by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are held by institutional investors. 25.7% of Athira Pharma shares are held by insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Athira Pharma and Athira Pharma both had 1 articles in the media. Athira Pharma's average media sentiment score of 1.82 beat Cardiol Therapeutics' score of 1.79 indicating that Athira Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Athira Pharma	Very Positive
Cardiol Therapeutics	Very Positive

Summary

Athira Pharma and Cardiol Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

Get Athira Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LONA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LONA vs. The Competition

Export

Metric	Athira Pharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$57.32M	$12.43B	$7.28B	$13.01B
Dividend Yield	N/A	2.63%	2.51%	22.89%
P/E Ratio	-1.45	807.81	275.44	25.42
Price / Sales	N/A	748.21	559.80	78.81
Price / Cash	N/A	86.65	77.16	53.04
Price / Book	2.05	9.19	10.66	5.96
Net Income	-$105.61M	$2.84B	$3.50B	$380.62M
7 Day Performance	4.72%	-3.85%	-3.65%	-3.75%
1 Month Performance	-18.27%	-7.95%	-8.06%	-6.62%
1 Year Performance	N/A	-5.71%	2.58%	-4.38%

Athira Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LONA Athira Pharma	3.7314 of 5 stars	$6.11 -5.1%	$17.33 +183.9%	N/A	$57.32M	N/A	N/A	19	Positive News
ACOG Alpha Cognition	3.6621 of 5 stars	$8.98 -1.9%	$18.00 +100.4%	+24.8%	$199.27M	$15.26M	N/A	71	Short Interest Increase
ZNTL Zentalis Pharmaceuticals	3.4354 of 5 stars	$2.67 -4.0%	$7.50 +180.9%	+48.1%	$199.25M	$67.43M	N/A	106
DERM Journey Medical	1.7114 of 5 stars	$6.16 -7.9%	$14.00 +127.3%	-18.9%	$188.82M	$61.86M	N/A	58
NERV Minerva Neurosciences	1.7031 of 5 stars	$3.43 +3.3%	$10.33 +201.3%	-0.4%	$158.52M	N/A	N/A	7	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LONA) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Athira Pharma (LONA) Competitors

LONA vs. ACOG, ZNTL, DERM, NERV, and CRDL

How does Athira Pharma compare to Alpha Cognition?

Summary

How does Athira Pharma compare to Zentalis Pharmaceuticals?

Summary

How does Athira Pharma compare to Journey Medical?

Summary

How does Athira Pharma compare to Minerva Neurosciences?

Summary

How does Athira Pharma compare to Cardiol Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LONA vs. The Competition

Athira Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Athira Pharma (LONA) Competitors

LONA vs. ACOG, ZNTL, DERM, NERV, and CRDL

How does Athira Pharma compare to Alpha Cognition?

Do analysts prefer LONA or ACOG?

Which has preferable valuation and earnings, LONA or ACOG?

Is LONA or ACOG more profitable?

Do institutionals & insiders believe in LONA or ACOG?

Which has more risk & volatility, LONA or ACOG?

Does the media prefer LONA or ACOG?

Summary

How does Athira Pharma compare to Zentalis Pharmaceuticals?

Which has more volatility & risk, LONA or ZNTL?

Do institutionals & insiders have more ownership in LONA or ZNTL?

Is LONA or ZNTL more profitable?

Which has better valuation & earnings, LONA or ZNTL?

Do analysts recommend LONA or ZNTL?

Does the media prefer LONA or ZNTL?

Summary

How does Athira Pharma compare to Journey Medical?

Which has more volatility and risk, LONA or DERM?

Do institutionals and insiders have more ownership in LONA or DERM?

Is LONA or DERM more profitable?

Which has higher earnings and valuation, LONA or DERM?

Does the media prefer LONA or DERM?

Do analysts recommend LONA or DERM?

Summary

How does Athira Pharma compare to Minerva Neurosciences?

Do insiders and institutionals hold more shares of LONA or NERV?

Is LONA or NERV more profitable?

Do analysts prefer LONA or NERV?

Which has more risk and volatility, LONA or NERV?

Which has higher valuation and earnings, LONA or NERV?

Does the media refer more to LONA or NERV?

Summary

How does Athira Pharma compare to Cardiol Therapeutics?

Do analysts recommend LONA or CRDL?

Which has stronger earnings and valuation, LONA or CRDL?

Which has more volatility & risk, LONA or CRDL?

Is LONA or CRDL more profitable?

Do institutionals & insiders believe in LONA or CRDL?

Does the media prefer LONA or CRDL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LONA vs. The Competition

Athira Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools